Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome? - Wikidata - wikimedia - TriplyDB

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

http://www.wikidata.org/entity/Q53239567

about

Timing of Adjuvant Chemotherapy and Impact on Survival for Resected Gastric Cancer.Effect of Early Adjuvant Chemotherapy on Survival of Advanced Gastric Cancer Patients: a Propensity Score-matched Analysis.Adjuvant Chemotherapy: What's the Rush?

P2860

Q51737586-3B7D5706-4E63-465E-AC54-85650CC6714A Q52720767-09D910BD-05C4-4116-9452-E2ED93AB88B6 Q54119749-4CA4DAFD-92D6-4BB1-A405-BE4FACA00E0E

P2860

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

http://www.wikidata.org/entity/Q53239567

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

@en

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

@nl

type

label

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

@en

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

@nl

prefLabel

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

@en

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

@nl

P1433

Q53239567-911A0B8B-25A2-4D31-8564-1C34C858A624

P1476

Q53239567-9EFAF83F-A778-4CF3-8C33-60C032B61E1F

P2093

Q53239567-3D2C9871-D2F4-40E4-A5F2-F2AFF47B9750

Q53239567-47861BD9-A614-47F6-AB09-A6DE3EE70980

Q53239567-651B9501-B6DB-42FE-BB28-7B55E82E96DA

Q53239567-6C62AC48-266F-4180-8641-7E0FE836FBD3

Q53239567-920F9AC5-7A52-46E2-ADF6-88F3BB864AA6

Q53239567-B070D166-8FC6-45FF-9E45-03259EF5B921

Q53239567-D005D62F-BB8F-496C-8C8F-4C1AAE79720D

Q53239567-D1C3BE7D-A55D-4F8A-97D2-BE2804A9481D

Q53239567-D3315C1F-6A2B-4386-BF37-35AC0569E9B1

Q53239567-E7101E23-B0C1-415F-948B-AE7C4AA33D24

P2860

Q53239567-23BD5181-DABA-4FE3-A502-185363362251

Q53239567-27DD5731-0D27-43A9-823E-673BBF680394

Q53239567-3790AC7E-7BC5-4EFA-B1F4-51491A88BBF9

Q53239567-786A28C2-0788-4910-A63D-E219273D8099

Q53239567-866425D1-F6EE-49B4-AA3A-BD67CFD54221

Q53239567-879BB39E-496D-4C51-802B-06483C687F44

Q53239567-87ACB413-7C36-4EF5-972A-2675BFD7B649

Q53239567-BAA605BA-2C6D-47AB-AE74-872F879111E9

Q53239567-BC73A7C0-6634-453E-9B45-FED6E3CCB5AE

Q53239567-D065239C-6F52-4732-8CEE-161C6C76A475

P304

Q53239567-1D21CF6A-592A-4E9D-8BB7-8D20EF65CB86

P31

Q53239567-04A3B433-6300-47A4-8794-4F39F3FFCE0B

P356

Q53239567-FAA29F8D-54C2-4580-A085-995D62E14529

P433

Q53239567-6560EAEF-CD46-4F66-BBE3-CB0D47375406

P478

Q53239567-969FDA7D-017C-47E2-8F43-CE48112CF788

P50

Q53239567-C9118553-C514-4F11-A3AC-0F11F18162EC

P577

Q53239567-C68EF65F-589C-4189-99BA-3D302836D94D

P5875

Q53239567-FC863FFD-AF70-4D00-AFF8-BED98C38D933

P698

Q53239567-82448BA8-5983-438B-B79E-DE26552FBBE2

P921

Q53239567-B2051734-5312-4EFB-8253-FFA4A39EF52D

P356

0284186X.2014.1000467

P1433

Acta Oncologica

P1476

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

@en

P2093

Ga Won Song

http://www.w3.org/2001/XMLSchema#string

Jae Ho Han

http://www.w3.org/2001/XMLSchema#string

Jin-Hyuk Choi

http://www.w3.org/2001/XMLSchema#string

Joon Seong Park

http://www.w3.org/2001/XMLSchema#string

Mi Sun Ahn

http://www.w3.org/2001/XMLSchema#string

Sang Uk Han

http://www.w3.org/2001/XMLSchema#string

Seok Yun Kang

http://www.w3.org/2001/XMLSchema#string

Seong Hyun Jeong

http://www.w3.org/2001/XMLSchema#string

Seung Soo Sheen

http://www.w3.org/2001/XMLSchema#string

Yong Kwan Cho

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

5-Fluorouracil, mitomycin-c, and polysaccharide-k versus uracil-ftorafur and polysaccharide-K as adjuvant chemoimmunotherapy for patients with locally advanced gastric cancer with curative resection.

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis.

Adjuvant therapy for gastric cancer.

Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer.

Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201).

Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.

Adjuvant chemotherapy for stage III colon cancer: does timing matter?

Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer.

P304

1231-1234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/0284186X.2014.1000467

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271222369

http://www.w3.org/2001/XMLSchema#string

P698

25608823

http://www.w3.org/2001/XMLSchema#string

P921